http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#Head http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g http://www.nanopub.org/nschema#hasAssertion http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#assertion http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g http://www.nanopub.org/nschema#hasProvenance http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#provenance http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g http://www.nanopub.org/nschema#hasPublicationInfo http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#pubinfo http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#assertion http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_1 http://semanticscience.org/resource/SIO_000139 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_2 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_1 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://amigo.geneontology.org/amigo/term/GO:0016301 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_2 http://purl.obolibrary.org/obo/RO_0002204 http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=3236 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_3 http://purl.obolibrary.org/obo/BFO_0000066 http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_3 http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_1 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_3 http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate http://www.selventa.com/vocabulary/directlyDecreases http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_3 http://www.w3.org/1999/02/22-rdf-syntax-ns#subject http://www.ebi.ac.uk/chebi/searchId.do?chebiId=49668 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_3 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#assertion http://www.w3.org/2000/01/rdf-schema#label a(CHEBI:gefitinib) =| kin(p(HGNC:EGFR)) http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#provenance http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/description Approximately 61,000 statements. http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/rights Copyright (c) 2011-2012, Selventa. All rights reserved. http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/title BEL Framework Large Corpus Document http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/pav/authoredBy http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_5 http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://purl.org/pav/version 1.4 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_4 http://www.w3.org/ns/prov#value A multitude of synthetic tyrosine kinase inhibitors have been developed and screened for potential preclinical activity, most of which reversibly compete with ATP for binding to the enzyme's intracellular catalytic domain. The quinazoline derivatives ZD1839 (gefitinib, Iressa) and OSI- 774 (erlotinib, Tarceva) appear to be the most promising to date. ZD1839 is a synthetic anilinoquinazoline [4-(3-chloro-4- fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy) quinazoline] that inhibits the EGFR tyrosine kinase, resulting in G1 cell cycle arrest and upregulation of the p27KIP1 cyclin dependent kinase inhibitor [88-91] http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_4 http://www.w3.org/ns/prov#wasQuotedFrom http://www.ncbi.nlm.nih.gov/pubmed/15320717 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_5 http://www.w3.org/2000/01/rdf-schema#label Selventa http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#assertion http://www.w3.org/ns/prov#hadPrimarySource http://www.ncbi.nlm.nih.gov/pubmed/15320717 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#_4 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g#pubinfo http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g http://purl.org/dc/terms/created 2014-07-03T14:30:27.054+02:00 http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g http://purl.org/pav/createdBy http://orcid.org/0000-0001-6818-334X http://www.tkuhn.ch/bel2nanopub/RAG_HO39-JQewciArwaTJtqcVGzWCtZITlHbya-KfOU1g http://purl.org/pav/createdBy http://orcid.org/0000-0002-1267-0234